Stay updated with breaking news from Jonathan Aschoff. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Operator: Greetings, welcome to the Moleculin Biotech 2023 Year-End Conference Call and Webcast. [Operator Instructions] Please note, that this conference is being recorded.
Following news of an acquisition, Roth MKM analyst Jonathan Aschoff remains bullish on First Wave BioPharma
Roth MKM believes 2024 could prove to be a volatile year for stocks. Here are some of the firm's top picks.
Texas Biotech Advances Lead Candidate in Resistant AML
Drugs Show Anti-Cancer Effects on Myeloma Cells